Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
The most effective method to Decide the Best Auto Crash Attorney for Your Lawful Necessities- Email Promoting Instruments for Compelling Efforts
- Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift
- Experience Is standing by: History's Most noteworthy Travelers
- Popular Home Rug Series For You
- ‘Downton Abbey: The Grand Finale’ hits streaming: How to watch, cast info and everything you need to know
- Turning into a Sharp Financial backer: Individual budget Wins
- 8 Espresso Bean Starting points All over the Planet
- Father and son spending Christmas together after health scares
